When evaluating botulinum toxin treatments for medical tourism, understanding the fundamental differences between Xeomin and Daxxify helps you have more.
Last reviewed: 2026-05-06
11 min read
Ready to explore your options in Istanbul?
Connect with our coordination team for a personalised treatment plan, verified provider matching, and travel logistics support.
Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
Key takeaways
Xeomin and Daxxify are FDA-approved botulinum toxin products with distinct formulations—Xeomin contains pure neurotoxin while Daxxify uses peptide excipient technology.
Providers must be licensed medical professionals with specific training in botulinum toxin administration; cosmetic-only training is insufficient.
Verify provider credentials, product authenticity, and facility accreditation before treatment—especially when traveling internationally.
Daxxify's longer duration (median 24 weeks) may reduce return visit frequency, a consideration for medical tourists.
Request complete documentation including product name, lot number, units administered, and injection sites for your records.
Understanding Xeomin and Daxxify — Core Context
When evaluating botulinum toxin treatments for medical tourism, understanding the fundamental differences between Xeomin and Daxxify helps you have more informed conversations with providers. Both products have FDA approval and established safety profiles, but they differ in molecular composition, duration of effect, and regulatory history [S1][S6]. For a broader understanding of the category, see our injectables and botulinum toxin hub.
What Makes These Products Different
Xeomin (incobotulinumtoxinA) contains only the pure 150 kDa neurotoxin without complexing proteins, earning it the designation of a "naked" or "free" neurotoxin. This purification process may reduce the potential for immunogenicity (antibody formation) compared to products containing complexing proteins [S1]. The absence of these proteins means Xeomin has a more streamlined molecular structure, which some providers note may be relevant for patients with sensitivities to other formulations [S4].
Daxxify (daxibotulinumtoxinA-lanm) employs a proprietary peptide excipient (RTP004) that stabilizes the neurotoxin without human serum albumin. This technology represents a departure from traditional botulinum toxin formulations and contributes to Daxxify's notably longer duration of effect in clinical trials [S2][S3]. The peptide excipient is designed to maintain neurotoxin stability during storage and administration, which may influence how the product performs once injected [S7].
These molecular differences have practical implications. Botulinum toxin type A products are not interchangeable, and dosing ratios vary between formulations [S5]. A provider should not simply substitute one product for another without adjusting units and injection sites accordingly. Understanding these distinctions helps you recognize whether your provider is following appropriate protocols.
Product Selection Considerations
The choice between Xeomin and Daxxify depends on multiple factors including desired duration, previous treatment response, and anatomical considerations. Neither product is universally "better"—the optimal choice varies by individual.
FDA Approval Timeline and Current Indications
Xeomin received its initial FDA approval in July 2010 for treating cervical dystonia and blepharospasm in adults. In July 2024, the FDA expanded approval to make Xeomin the first neurotoxin indicated for simultaneous treatment of upper facial lines, including glabellar lines, forehead lines, and crow's feet [S6]. This expansion reflects accumulated clinical evidence supporting its efficacy across multiple treatment areas.
Daxxify received initial FDA approval in September 2022 for the temporary improvement of moderate to severe glabellar lines in adults. The approval was based on the SAKURA Phase 3 clinical trials, which demonstrated statistically significant improvement compared to placebo [S3]. In August 2023, the FDA expanded approval to include treatment of cervical dystonia, broadening the therapeutic applications beyond aesthetic use [S7].
For medical tourists, understanding these approval timelines provides context for discussing treatment options with providers. Products may have different regulatory statuses in different countries, and verifying local approvals is an important part of treatment planning.
Accreditation Standards for Injectors
Who Is Legally Permitted to Administer These Products
Botulinum toxin injections are medical procedures that require administration by licensed healthcare professionals. The specific credentials that authorize injection vary by jurisdiction, but generally include physicians (MD, DO), physician assistants, nurse practitioners, registered nurses, and dentists who have received appropriate training [S8]. The common denominator across regulations is that injectors must hold a valid medical license with scope of practice that includes injectable treatments. You can verify credentials through our provider directory.
Credential Verification
When evaluating a provider, confirm that they hold an active medical license in good standing and have documented training specific to botulinum toxin injection techniques.
The distinction between medical professionals and non-medical practitioners is legally significant in most countries. Cosmetic-only training, while potentially useful for technique refinement, does not substitute for medical education and licensure [S8]. Medical training provides foundational knowledge of anatomy, physiology, pharmacology, and emergency response that is essential for safe injection practice.
For international patients, credential verification may require additional steps. Licensing databases and professional organization directories can help confirm a provider's standing. Many countries maintain online registries where you can verify medical licenses.
Training and Certification Requirements
Beyond basic licensure, competent botulinum toxin administration requires specialized training. This training typically covers facial anatomy, injection technique, dosing principles, contraindications, adverse event recognition, and management [S8]. Hands-on clinical experience under supervision is a critical component of this education.
Continuing education is also important in this field. New products, techniques, and safety data emerge regularly, and providers should demonstrate ongoing learning. Professional organizations often offer conferences, workshops, and certification programs that help injectors maintain current knowledge.
When researching providers, inquire about their specific training background, including the number of procedures they have performed and any specialized certifications they hold. A provider who can articulate their training and ongoing education is demonstrating commitment to competent practice.
Clinical Evidence — What the Data Shows
Efficacy Profiles
Clinical trials provide the evidence base for understanding how these products perform. For Xeomin, studies have demonstrated noninferiority to onabotulinumtoxinA (Botox) with a generally consistent 1:1 conversion ratio reported in the literature [S1][S4]. The July 2024 FDA expansion for simultaneous treatment of multiple upper facial areas was supported by clinical data demonstrating efficacy across these treatment sites [S6].
Daxxify's pivotal Phase 3 trials (SAKURA 1 and SAKURA 2) demonstrated efficacy in glabellar line improvement, with statistically significant results compared to placebo [S3]. The SAKURA 3 open-label study, which included 2,691 subjects with repeat treatments, confirmed a median duration of effect of 24 weeks [S2]. This longer duration compared to the 3-4 month range typical of other botulinum toxin products may influence treatment planning for some patients.
Interpreting Clinical Data
Clinical trial populations and conditions may differ from real-world practice. Individual response can vary based on anatomy, injection technique, product handling, and other factors.
Responder rates in clinical trials have shown that a substantial proportion of treated patients achieve meaningful improvement. However, the specific percentage achieving various improvement levels depends on the trial design, assessment scales used, and chosen endpoints. Discuss realistic expectations with your provider based on your specific treatment goals. Explore our treatment options page for more information on related therapeutic uses.
Safety Considerations
Both products have established safety profiles based on clinical trial data and post-market experience. Common adverse events for botulinum toxin injections include temporary injection-site reactions such as redness, swelling, and bruising [S1]. More uncommon effects may include headache, eyebrow droop, or asymmetric results, which are typically temporary but may require correction.
Xeomin's pure neurotoxin formulation has been discussed in the literature as potentially having reduced immunogenicity compared to products with complexing proteins [S1][S4]. The clinical significance of this theoretical advantage varies between patients and depends on factors including treatment frequency and individual immune response patterns.
Daxxify's safety profile has been evaluated in clinical trials, with adverse events generally consistent with the botulinum toxin class [S2][S3]. As a newer product, long-term safety data beyond the clinical trial periods is still accumulating [S3]. The peptide excipient technology is designed to avoid human serum albumin, which may be relevant for patients with specific concerns about blood-derived products.
Botulinum toxin products carry boxed warnings about potential spread beyond the injection site, though this is rare with proper administration. Contraindications include certain neuromuscular conditions, pregnancy, and known hypersensitivity to product components [S5]. A thorough pre-treatment consultation should cover your complete medical history.
Treatment Protocols and Decision Criteria
Choosing the Right Product
Product selection involves discussion between you and your provider based on multiple factors. Daxxify's longer duration may appeal to patients seeking less frequent maintenance treatments, which can be advantageous for medical tourists who face travel logistics for return visits [S2]. However, this extended duration also means that any adverse effects or unsatisfactory results persist longer.
Previous treatment history is another consideration. Patients who have responded well to one botulinum toxin product may prefer to continue with that option, as provider familiarity and established dosing patterns can contribute to predictable outcomes. Switching products requires careful consideration of dosing equivalency, which is not precisely established between all formulations [S5].
Your anatomical characteristics, treatment goals, and lifestyle factors all influence which product may be more suitable. A provider who presents options rather than insisting on a single product demonstrates appropriate clinical judgment and respect for patient autonomy.
Protecting Yourself as a Medical Tourist
Questions to Ask Your Provider
Before committing to treatment, asking targeted questions helps you assess provider competence and facility standards. Request information about the provider's medical license and specific training in botulinum toxin administration, including how many procedures they have performed [S8]. A qualified provider should be comfortable answering these questions and may voluntarily provide credentials and before-and-after documentation. Our accredited facilities directory can help you identify appropriate treatment locations.
Red Flags
Guaranteed outcomes or "risk-free" language
Pressure to book immediately without consultation
Inability or unwillingness to show product packaging
No clear process for addressing adverse reactions
Refusal to provide written documentation of treatment details
Inquire about product authenticity and storage procedures. Products should arrive in sealed manufacturer packaging and be stored according to label requirements. Ask to see the product before administration and confirm that it will be drawn from a newly opened vial.
Discuss the provider's protocol for managing adverse events. Understanding how complications would be addressed—and whether follow-up support is available if you have returned home—provides important peace of mind for international patients.
Documentation to Request
After treatment, detailed documentation protects you and supports future care. Request written records including the exact product name, lot number, and expiration date. The lot number is particularly important for tracking purposes should any product quality concerns emerge [S5].
Record the number of units administered at each injection site, along with the specific anatomical locations treated. This information helps future providers understand your treatment history and plan appropriate dosing if you switch products or providers.
Include the date of treatment and your provider's contact information in your records. Ask for any written aftercare instructions provided, and clarify the timeline and process for follow-up if needed.
Action Checklist
Before Your Appointment
Research provider credentials and verify medical licensure in the relevant jurisdiction
Confirm that the specific products are approved for use in your destination country
Prepare a complete medical history including previous reactions, current medications, and neuromuscular conditions
Establish clear expectations with your provider before traveling if possible
At Your Appointment
Confirm product authenticity and verify packaging is intact
Request written treatment documentation before leaving the facility
Review and understand all aftercare instructions
Know the process for contacting your provider with questions after departure
After Treatment
Monitor injection sites for unexpected reactions and report concerns promptly
Document your results with photographs and notes for future reference
Plan follow-up timing based on expected duration and your travel schedule
Contact your provider immediately for any signs of unusual swelling, weakness, or breathing difficulties
For international patients, our travel coordination services can help manage follow-up care logistics after you return home.
1.Park J, Lee MS, Harrison AR. “Profile of Xeomin (incobotulinumtoxinA) for the treatment of blepharospasm.” Clinical Ophthalmology. 2011. Accessed 2026-02-20.https://pmc.ncbi.nlm.nih.gov/articles/PMC3116796/
2.Fabi SG, Cohen JL, Green LJ, et al.. “DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3.” Dermatologic Surgery. 2021. Accessed 2026-02-20.https://pmc.ncbi.nlm.nih.gov/articles/PMC7752211/
3.Carruthers JD, Fagien S, Joseph JH, et al.. “DaxibotulinumtoxinA in the treatment of glabellar lines: results from SAKURA 1 and SAKURA 2.” Plastic and Reconstructive Surgery. 2020. Accessed 2026-02-20.https://pmc.ncbi.nlm.nih.gov/articles/PMC6940025/
4.Field M, Splevins A, Picaut P, et al.. “AbobotulinumtoxinA, OnabotulinumtoxinA, and IncobotulinumtoxinA neurotoxin content and duration implications.” Toxins. 2018. Accessed 2026-02-20.https://pmc.ncbi.nlm.nih.gov/articles/PMC6316182/
5.Brin MF, James C, Maltman J.. “Botulinum toxin type A products are not interchangeable: a review of the evidence.” Biologics. 2014. Accessed 2026-02-20.https://pmc.ncbi.nlm.nih.gov/articles/PMC4199839/
